...
首页> 外文期刊>Pharmacogenetics and genomics >The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)
【24h】

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)

机译:ABCC2和SLCO1B3基因多态性与多西他赛药代动力学和中性粒细胞减少的关系:CALGB 60805(联盟)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Docetaxel-related neutropenia was associated with polymorphisms in the drug transporters ABCC2 and SLCO1B3 in Japanese cancer patients. We hypothesized that this association is because of reduced docetaxel clearance, associated with polymorphisms in those genes. We studied 64 US cancer patients who received a single cycle of 75 mg/m of docetaxel monotherapy. We found that the ABCC2 polymorphism at rs-12762549 trended to show a relationship with reduced docetaxel clearance (P=0.048), but not with neutropenia. There was no significant association of the SLCO1B3 polymorphisms with docetaxel clearance or neutropenia. We conclude that the relationship between docetaxel-associated neutropenia and polymorphisms in drug transporters identified in Japanese patients was not confirmed in this cohort of US cancer patients.
机译:多西他赛相关的中性粒细胞减少症与日本癌症患者药物转运蛋白ABCC2和SLCO1B3的多态性有关。我们假设这种关联是由于多西他赛清除率降低,与这些基因的多态性有关。我们研究了64位接受多西他赛单药75 mg / m单周期治疗的美国癌症患者。我们发现rs-12762549处的ABCC2多态性倾向于显示与多西他赛清除率降低相关(P = 0.048),但与中性粒细胞减少无关。 SLCO1B3多态性与多西他赛清除率或中性粒细胞减少没有显着相关性。我们得出的结论是,在这一美国癌症患者队列中,未证实多西他赛相关的中性粒细胞减少与日本患者中确定的药物转运蛋白的多态性之间的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号